The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.

@article{Harris1999TheWH,
  title={The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.},
  author={Nancy Lee Harris and Elaine S. Jaffe and Jacques Diebold and Georges Flandrin and H. Konrad Muller-Hermelink and James W. Vardiman and T. Andrew Lister and Clara Derber Bloomfield},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1999},
  volume={10 12},
  pages={
          1419-32
        }
}
  • N. HarrisE. Jaffe C. Bloomfield
  • Published 1 December 1999
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
INTRODUCTION Since 1995, the European Association of Pathologists (EAHP) and the Society for Hematopathology (SH) have been developing a new World Health Organization (WHO) Classification of hematologic malignancies. The classification includes lymphoid, myeloid, histiocytic, and mast cell neoplasms. DESIGN The WHO project involves 10 committees of pathologists, who have developed lists and definitions of disease entities. A Clinical Advisory Committee (CAC)) of international hematologists… 

The World Health Organization (WHO) classification of the myeloid neoplasms.

The purpose of this communication is to outline briefly the WHO classification of malignant myeloid diseases, to draw attention to major differences between it and antecedent classification schemes, and to provide the rationale for those differences.

The new World Health Organization classification of lymphomas: the past, the present and the future

  • J. Chan
  • Medicine
    Hematological oncology
  • 2001
The lymphoma component of the classification is merely an update of the REAL classification, with minor changes necessitated by new information that has become available since its proposal.

The World Health Organization classification of lymphomas.

The incidence of different histological types of non-Hodgkin s lymphomas diagnosed in Zagreb University Hospital Center were analyzed and a conceptual grouping of lymphomas into four categories (indolent, aggressive, highly aggressive, and localized indolent) was presented.

The World Health Organization Classification of Lymphomas

The incidence of different histological types of non-Hodgkin’s lymphomas diagnosed in Zagreb University Hospital Center were analyzed and a conceptual grouping of lymphomas into four categories (indolent, aggressive, highly aggressive, and localized indolent) was presented.

Current trends in the management of malignant lymphoma: new WHO classification, guidelines for high-dose therapy with HSCT, and new response criteria

  • K. Ohnishi
  • Medicine
    International Journal of Clinical Oncology
  • 2000
The new WHO classification of non-Hodgkin’s lymphoma adopts the REAL classification, with minor modifications and with a reassessment of the provisional categories.

Realistic pathologic classification of acute myeloid leukemias.

  • D. Arber
  • Medicine
    American journal of clinical pathology
  • 2001
A realistic pathologic classification for AML is proposed that includes disease types that correlate with specific cytogenetic translocations and can be recognized reliably by morphologic evaluation and immunophenotyping and that incorporates the importance of associated myelodysplastic changes.

Classification of Canine Malignant Lymphomas According to the World Health Organization Criteria

A study was carried out to test the accuracy and consistency of veterinary pathologists, not specialists in hematopathology, in applying the World Health Organization (WHO) system of classification

Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients.

The study confirmed that the EORTC classification allows a better management of patients with PCL and small amendments to that classification should be carried out to account for recently described entities and to unify some of the diagnostic categories.

Clinical Characteristics and Pathological Classification of Non-Hodgkin's Lymphoma in Kuwait. Results of a Collaborative Study with the International Lymphoma Study Group (ILSG)

The intense cooperation between experts of the ISLG and pathologists of the KCCC proved that the WHO classification of neoplastic disease of the hematopoietic and lymphoid tissues was fully reproducible in Kuwait.

Update on classification of lymphomas

The International Lymphoma Study Group developed a consensus list of lymphoid neoplasms, which was published in 1994 as the Revised European-American Classification of Lymphoid Neoplasms (REAL), based on the principle that a classification is a list of real disease entities, which are defined by a combination of morphology, immunophenotype, genetic features, and clinical features.
...

References

SHOWING 1-10 OF 31 REFERENCES

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

  • J. ArmitageD. Weisenburger
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
The findings for the 13 most common lymphoma types that will be encountered in clinical practice are presented and it is important that clinicians be knowledgeable with regard to their clinical characteristics.

Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.

  • V. DiehlM. Sextro H. Stein
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
The two subgroups of LPHD and LRCHD bore a close clinical resemblance that was distinct from CHD; the course was similar to that of comparable nodular sclerosis and mixed cellularity patients.

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.

  • M. ShippM. Abeloff B. Coiffier
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
The jury made a positive or negative recommendation or indicated that there were insufficient data to make a recommendation on when and how to perform HDT in aggressive non-Hodgkin’s lymphomas.

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.

There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies and NHL patients age > or = 40 years at the time of transplant and who received TBI are at greatest risk.

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Excerpt The first proposals for the morphologic classification of the acute leukemias by the French-American-British (FAB) group (1) were put forward in the hope that they might serve as a basis fo...

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

It is shown that there is diversity in gene expression among the tumours of DLBCL patients, apparently reflecting the variation in tumour proliferation rate, host response and differentiation state of the tumour.

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

This is the first report demonstrating the safety and efficacy of Rituxan anti-CD20 chimeric antibody in combination with standard-dose systemic chemotherapy in the treatment of indolent B-cell lymphoma.

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy, and further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.

Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

The addition of interferon alfa to a regimen containing doxorubicin increased the rate of response, event-free survival, and overall survival in patients with advanced follicular non-Hodgkin's lymphoma, without serious toxicity, although some patients were unable to tolerate the side effects.